Table 1.
Evolution of clinical features from illness onset and taking pirfenidone (2 months after onset).
| Clinical features | Before COVID-19 | Acute stage | At discharge (4 months after onset) | 1 year after onset | 2 years after onset |
|---|---|---|---|---|---|
| Symptoms | |||||
| Fever | √ | ||||
| Cough | √ | √ | √ | √ | |
| Dyspnoea | √ | √ | √ | √ | |
| Headache | √ | ||||
| Fatigue | √ | √ | √ | √ | |
| Myalgia | √ | √ | √ | ||
| Nausea/Vomiting | √ | ||||
| Diarrhea | √ | ||||
| Chest pain | √ | √ | √ | √ | |
| Anosmia | √ | √ | |||
| Dysgeusia | √ | √ | |||
| Other | √ | √ | |||
| Pulmonary rale | / | Moist rale | Velcro rale | Velcro rale | Velcro rale |
| mMRC, level | 0 | / | 4 | 3 | 2 |
| 6-MWD, m | / | / | /* | 188 | 309 |
| HADS score | |||||
| Anxiety | / | / | / | 1 | 0 |
| Depression | / | / | / | 0 | 0 |
| AIS Score | / | / | / | 10 | 2 |
| SF-36 score | |||||
| Physical functioning | / | / | / | 25 | 85 |
| Role-physical | / | / | / | 0 | 100 |
| Bodily pain | / | / | / | 72 | 74 |
| General health | / | / | / | 35 | 55 |
| Vitality | / | / | / | 55 | 85 |
| Social functioning | / | / | / | 37.5 | 87.5 |
| Role-emotional | / | / | / | 100 | 100 |
| Mental health | / | / | / | 84 | 92 |
| Health transition | / | / | / | 75 | 75 |
| Pulmonary function | |||||
| FVC, L | / | / | /* | 1.98 | 2.30 |
| FEV1, L | / | / | /* | 1.64 | 1.80 |
| FEV1/FVC | / | / | /* | 0.82 | 0.83 |
| TLC, % of predict | / | / | /* | 61.7 | 72.3 |
| DLCO, % of predict | / | / | /* | 30.3 | 47.9 |
*
The patient can't tolerate it. mMRC, modified Medical Research Council Dyspnea Scale; 6-MWD, 6 Minutes Walk Test Distance; HADS, Hospital Anxiety and Depression Scale; AIS, Athens Insomnia Scale; SF-36, Chinese vision of the 36-Item Short Form Health Survey questionnaire; FVC, Forced Vital Capacity; FEV1, Forced Expiratory Volume in 1 s; TLC, Total Lung Capacity; DLCO, Diffusion Capacity for Carbon monoxide.